2019
Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer
Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e1917062. PMID: 31808928, PMCID: PMC6902768, DOI: 10.1001/jamanetworkopen.2019.17062.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerTNM staging systemDisease-free survivalHigh-risk patientsCell lung cancerStaging systemEighth editionSurgical resectionLung cancerConventional TNMPrognostic classifierNonsquamous non-small cell lung cancerQuaternary care medical centerDisease-free survival ratesHigh molecular riskSurvival 3 yearsEarly-stage diseaseConventional TNM stagingCritical unmet needCohort studyPrimary outcomeConsecutive seriesTNM stagingMolecular riskConcordance index
2017
2460
Wang S, Woodard G, Lucas C, Rogers S, Jablons D. 2460. Journal Of Clinical And Translational Science 2017, 1: 79-79. PMCID: PMC6799655, DOI: 10.1017/cts.2017.280.Peer-Reviewed Original ResearchIvor Lewis esophagectomyILE patientsAntibiotic durationAntibiotic prophylaxisPostoperative pneumoniaRate of pneumoniaRetrospective cohort studyShort-term outcomesLength of stayFischer's exact testMedication administration recordsInvasive surgical proceduresHospital stayCohort studySecondary outcomesPrimary outcomeRespiratory infectionsAntibiotic stewardshipPatient outcomesSurgical proceduresHigh incidencePneumoniaExact testPatientsAdministration records